William William, MD, The University of Texas MD Anderson Cancer Centre, Houston, TX, discusses the current developments in antibody-drug conjugates (ADC) for non-small cell lung cancer (NSCLC). ADCs are a growing field with new drugs being developed for different targets, such as HER2 and HER3. Trastuzumab deruxtecan is a major ADC for NSCLC treatment due to impressive response rates in patients with HER2 mutations. ADCs targeting tumour-associated calcium signal transducer 2 (TROP-2) have also shown promising results in NSCLC. Dr William comments on datopotamab deruxtecan, a TROP-2 ADC, which has generated impressive response rates combined with chemoimmunotherapy in the first-line setting. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть